Polypeptide dimer having high sialic acid content and containing the extracellular domain of the alpha subunit of the IgE Fc receptor and pharmaceutical composition containing the same

A polypeptide dimer with high sialic acid content, derived from the IgE Fc receptor, addresses the inefficacies and side effects of current treatments by enhancing IgE binding and reducing adverse reactions, offering a safer and more effective treatment for allergic diseases.

JP7579815B2Active Publication Date: 2024-11-08GI INNOVATION INC
View PDF 11 Cites 0 Cited by

Patent Information

Application Number
JP2021575270
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-07-08
Filing Date
2020-07-07
Publication Date
2024-11-08
Estimated Expiration
2040-07-07

AI Technical Summary

Technical Problem

Current treatments for allergic diseases, such as allergic rhinitis and asthma, suffer from insufficient efficacy and significant side effects, particularly with high-dose administration of omalizumab, which can lead to adverse reactions like angioedema and anaphylactic responses.

Method used

Development of a polypeptide dimer with a high sialic acid content, derived from the extracellular domain of the alpha subunit of the IgE Fc receptor, exhibiting enhanced binding affinity for IgE and maintaining high concentrations in the blood, thereby minimizing side effects and extending administration cycles.

Benefits of technology

The polypeptide dimer with high sialic acid content demonstrates superior safety and durability, reducing anaphylaxis risk and maintaining effective IgE binding, making it a more effective and safer treatment option for allergic diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007579815000009
    Figure 0007579815000009
  • Figure 0007579815000010
    Figure 0007579815000010
  • Figure 0007579815000011
    Figure 0007579815000011
Patent Text Reader

Abstract

The present invention relates to a modified IgE Fc receptor with a high sialic acid content and a pharmaceutical composition comprising the same. Compared to conventional anti-IgE antibodies, the polypeptide dimer with a high sialic acid content of the present invention not only has superior safety and durability in the body, but also binds to IgE very strongly, offering the advantage of extending the administration cycle. Furthermore, the polypeptide dimer with a high sialic acid content of the present invention is an IgE-only targeting substance and, unlike conventional anti-IgE antibodies that use IgG1 Fc, does not bind to Fc gamma receptors. Therefore, it can inhibit the release of mediators triggered by binding to Fc gamma receptors on the surface of mast cells, thereby minimizing serious side effects. Furthermore, the polypeptide dimer with a high sialic acid content of the present invention can maintain high concentrations in the blood even when administered subcutaneously.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a polypeptide dimer comprising an IgE Fc receptor and having a high sialic acid content, and a pharmaceutical composition comprising the polypeptide dimer. [Background technology]

[0002] As modern society becomes industrialized and dietary habits become westernized, the incidence of allergic diseases, including asthma, allergic rhinitis, atopic dermatitis, and food allergies, is increasing. The incidence of anaphylaxis, a severe allergic disease, is also increasing. These chronic immune diseases significantly impair the quality of life of individuals, and the socio-economic costs are correspondingly increasing. Therefore, there is a strong need for a means to overcome such diseases.

[0003] Most allergic diseases are caused by an excessive immune response of immunoglobulin E (IgE). IgE is an antibody that is present in the blood at a very low concentration under normal conditions. IgE is also normally produced by harmless antigens. The number of IgE may increase without any particular stimulation. In such cases, allergic diseases may be led. An abnormally increased number of IgE can bind to high affinity IgE Fc receptors (FcεRIs) expressed on the surface of mast cells, basophils, etc. Such binding causes the mast cells or basophils to release chemical mediators such as histamine, leukotrienes, prostaglandins, bradykinin, and platelet activating factor. The release of these chemical mediators results in allergic symptoms. In particular, allergic diseases may show exacerbation of symptoms due to the binding between IgE and FcεRI. In addition, FcεRI expressing cells are known to increase in allergic patients.

[0004] Currently, various methods have been proposed to treat allergic diseases, such as avoiding allergens, administering anti-allergic drugs, regulating IgE synthesis in the body, and developing anti-IgE antibodies. However, many drawbacks still exist, such as insufficient efficacy of drugs and occurrence of serious side effects. Recently, a composition that can bind to IgE and FcγRIIb with high affinity and inhibit cells expressing membrane-anchored IgE has been researched. This composition has been reported to be useful for the treatment of IgE-mediated diseases, including allergies and asthma (KR10-1783272B).

[0005] In particular, omalizumab (trade name: Xolair), which targets the Fc portion of IgE antibodies, has been developed and used as a treatment for refractory severe asthma and refractory urticaria. However, high dose administration of omalizumab to maintain the therapeutic effect leads to high cost burden and side effects such as angioedema and anaphylactic reactions (The Journal of Clinical Investigation Volume 99, Number 5, March 1997, 915-925). In addition, post-marketing results have reported serious adverse reactions such as allergic granulomatous vasculitis and idiopathic severe thrombocytopenia. Summary of the Invention [Problem to be solved by the invention]

[0006] Therefore, the present inventors conducted research to develop a safe and effective therapeutic agent for allergic diseases. As a result, it was found that when the sialic acid content of a polypeptide dimer containing two monomers (FcεRIα-ECD) containing the extracellular domain of the alpha subunit of the IgE Fc receptor is high, the polypeptide dimer has excellent binding affinity to IgE and maintains a high concentration in the blood. In particular, it was confirmed that a polypeptide dimer having a high sialic acid content can be effectively delivered to the body even when administered subcutaneously, thereby completing the present invention. [Means for solving the problem]

[0007] In one embodiment of the invention, there is provided a polypeptide dimer comprising two monomers comprising the extracellular domain of the alpha subunit of the IgE Fc receptor (FcεRIα-ECD), with a sialic acid / polypeptide dimer molar ratio of at least 8.

[0008] In another aspect of the present invention, there is provided a pharmaceutical composition for preventing or treating an allergic disease, comprising a polypeptide dimer having a high content of sialic acid.

[0009] In another aspect of the present invention, a transdermal patch containing the pharmaceutical composition is provided.

[0010] In another aspect of the present invention, a topical patch containing the pharmaceutical composition is provided.

[0011] In another aspect of the present invention, there is provided a food composition for improving or alleviating allergic symptoms, comprising a polypeptide dimer having a high content of sialic acid.

[0012] In another aspect of the present invention, there is provided a use of a polypeptide dimer having a high content of sialic acid for preventing or treating an allergic disease. Effect of the Invention

[0013] The polypeptide dimer having a high sialic acid content according to the present invention not only has excellent safety and durability in the body compared with conventionally used anti-IgE antibodies, but also binds very strongly to IgE, and has the advantage of extending the administration cycle. In addition, the polypeptide dimer having a high sialic acid content according to the present invention is an IgE-only targeting substance, and does not bind to Fc gamma receptors, unlike conventional anti-IgE antibodies to which the Fc of IgG1 is applied. Therefore, it can inhibit the release of mediators caused by binding to Fc gamma receptors on the surface of mast cells, and as a result, it can minimize the occurrence of severe side effects, such as anaphylaxis, which can be caused by binding between IgG1 and Fc gamma receptor III of mast cells. In addition, the polypeptide dimer having a high sialic acid content can maintain a high concentration in the blood even when administered subcutaneously. Therefore, the polypeptide dimer having a high sialic acid content according to the present invention can be advantageously used in the prevention or treatment of allergic diseases. [Brief description of the drawings]

[0014] [Figure 1] FIG. 1 shows the results of confirming polypeptide dimers produced in each cell line by SDS-PAGE. [Diagram 2] FIG. 1 shows the results of SDS-PAGE for non-reduced and reduced forms of a polypeptide dimer according to one embodiment. [Diagram 3] FIG. 1 shows the binding affinity of Omalizumab to IgE. [Figure 4] FIG. 2 shows the binding affinity of a polypeptide dimer (IgETRAP) according to an embodiment of the present invention to IgE. [Figure 5a] FIG. 1 shows the binding affinity of a polypeptide dimer according to an embodiment of the invention (IgETRAP) or omalizumab to IgG Fc gamma receptor I (FcγRI). [Figure 5b]FIG. 1 shows the binding affinity of a polypeptide dimer according to an embodiment of the invention (IgETRAP) or omalizumab to IgG Fc gamma receptor IIA (FcγRIIA). [Figure 5c] FIG. 1 shows the binding affinity of a polypeptide dimer according to an embodiment of the invention (IgETRAP) or omalizumab to IgG Fc gamma receptor IIB (FcγRIIB). [Figure 5d] FIG. 1 shows the binding affinity of a polypeptide dimer according to an embodiment of the invention (IgETRAP) or omalizumab to IgG Fc gamma receptor IIIA (FcγRIIIA). [Figure 5e] FIG. 1 shows the binding affinity of a polypeptide dimer according to an embodiment of the invention (IgETRAP) or omalizumab to IgG Fc gamma receptor IIIB (FcγRIIIB). [Figure 6] 1 is a graph obtained by quantifying the binding affinity between a polypeptide dimer according to an embodiment of the present invention (IgETRAP) or Omalizumab and an IgG Fc gamma receptor. [Figure 7] FIG. 1 shows the degree of IgE binding depending on the concentration of a polypeptide dimer according to an embodiment of the present invention. [Figure 8] FIG. 1 shows a comparison between the inhibitory ability of a polypeptide dimer (IgETRAP) according to an embodiment of the present invention and Xolair (omalizumab) depending on the concentration thereof against the activity of human FcεRI-expressing mouse-derived mast cells. [Figure 9] FIG. 11 confirms the anti-allergic effect of a polypeptide dimer according to an embodiment of the present invention by measuring the frequency of diarrhea in a food allergy model. [Figure 10] FIG. 1 shows the results of SDS-PAGE for non-reduced and reduced forms of polypeptide dimers (SAlow, SAmedi and SAhigh) according to an embodiment of the present invention. [Figure 11] FIG. 11 confirms the isoelectric points of polypeptide dimers (SAlow, SAmedi and SAhigh) according to an embodiment of the present invention. [Figure 12]FIG. 11 confirms the anti-allergic effect of subcutaneous injection of a polypeptide dimer (SAlow and SAhigh) according to an embodiment of the present invention by measuring the frequency of diarrhea in a food allergy model. [Figure 13] FIG. 13 is a diagram confirming the anti-allergic effect of a polypeptide dimer (SAlow and SAhigh) according to an embodiment of the present invention by measuring the IgE concentration in the blood in a food allergy model. [Figure 14] FIG. 1 is a diagram confirming the anti-allergic effect of a polypeptide dimer (SAlow and SAhigh) according to one embodiment by measuring the blood MCPT-1 concentration in a food allergy model. [Figure 15] FIG. 1 shows the results of an analysis of the pharmacokinetic profile of a polypeptide dimer according to one embodiment as a function of sialic acid content in a mouse model. [Figure 16] FIG. 1 confirms the anti-allergic effect of a polypeptide-dimer according to an embodiment as a function of sialic acid content by measuring body temperature in a passive systemic anaphylaxis mouse model. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0015] In one aspect of the present invention, a polypeptide dimer having a high content of sialic acid is provided, comprising two monomers comprising the extracellular domain of the alpha subunit of the IgE Fc receptor (FcεRIα-ECD), wherein the monomers comprise an Fc region, the Fc region and the FcεRIα-ECD are linked via a hinge, and the polypeptide dimer is characterized in that it has a molar ratio of sialic acid / polypeptide dimer of at least 8.

[0016] As used herein, the term "IgE" refers to an antibody known as immunoglobulin E. IgE has affinity for mast cells, basophils, etc. In addition, the reaction between IgE and its corresponding antigen (allergen) causes an inflammatory response. In addition, IgE is known to be the primary cause of anaphylaxis.

[0017] As used herein, the term "IgE Fc receptor", also referred to as Fcε receptor, refers to a receptor that binds to the Fc portion of IgE. There are two types of receptors. The receptor with high affinity for IgE Fc is called Fcε receptor I (FcεRI). The receptor with low affinity for IgE Fc is called Fcε receptor II (FcεRII). FcεRI is expressed on mast cells and basophils. When IgE antibodies bound to FcεRI are cross-linked with multivalent antigens, degranulation occurs in mast cells and basophils, which results in the release of various chemical mediators, including histamine. This release leads to an immediate allergic reaction.

[0018] FcεRI is a membrane protein composed of one α chain, one β chain, and two γ chains linked by disulfide bonds. The part of these chains that binds IgE is the α chain (FcεRIα). FcεRIα is approximately 60 kDa in size and is composed of a hydrophobic domain present on the inner side of the cell membrane and a hydrophilic domain present on the outer side of the cell membrane. In particular, IgE binds to the extracellular domain of the α chain. FcεRIα can be used interchangeably as the alpha subunit of the IgE Fc receptor.

[0019] Specifically, the alpha subunit of the IgE Fc receptor may have the amino acid sequence set forth in NP_001992.1. Additionally, the extracellular domain of the alpha subunit of the IgE Fc receptor (FcεRIα-ECD) may have the amino acid sequence of SEQ ID NO: 1. The FcεRIα-ECD may be a fragment or variant of the FcεRIα-ECD, so long as the fragment or variant is capable of binding to IgE. Additionally, the FcεRIα-ECD of SEQ ID NO: 1 may be encoded by a polynucleotide having the sequence of SEQ ID NO: 5.

[0020] Variants can be prepared by methods that substitute, delete, or add one or more amino acids in the wild-type FcεRIα-ECD, so long as the methods do not alter the function of the FcεRIα-ECD. Such variants may be 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the amino acid sequence of SEQ ID NO:1.

[0021] The Fc region may be a wild-type Fc region or a modified Fc region. In addition, as used herein, the term "modified Fc region" refers to a region in which a part of the Fc portion of an antibody is modified. The Fc region refers to a protein that contains the heavy chain constant region 2 (CH2) and the heavy chain constant region 3 (CH3) of an immunoglobulin, but does not contain the variable regions of the heavy and light chains of the immunoglobulin and the light chain constant region 1 (CH1). In particular, the modified Fc region may be obtained by substituting some amino acids of the Fc region or by combining different types of Fc regions. Specifically, the modified Fc region may have the amino acid sequence of SEQ ID NO: 2. In addition, the modified Fc region of SEQ ID NO: 2 may be encoded by a polynucleotide having the sequence of SEQ ID NO: 6.

[0022] In addition, the altered Fc region may have native glycosylation or increased glycosylation compared to the native form. Immunoglobulin Fc glycosylation can be altered by conventional methods, including chemical, enzymatic, and microbial genetic engineering methods. In addition, the modified Fc region may be a region that lacks antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) functions due to the absence of binding sites for Fc gamma receptors (FcγR) or complement component 1q (C1q).

[0023] In one embodiment, the modified Fc region and FcεRIα-ECD may be linked via an IgD hinge. The hinge may be a hinge region derived from immunoglobulin IgD or a variant thereof. The natural IgD hinge region is composed of 64 amino acids. The hinge region derived from immunoglobulin IgD or a variant thereof may be composed of 20 to 60 consecutive amino acids, 25 to 50 consecutive amino acids, or 30 to 40 amino acids. The hinge variant may be obtained by modifying a part of the amino acid sequence of the IgD hinge region to minimize the occurrence of truncated forms during the protein production process.

[0024] In certain embodiments, the hinge region derived from immunoglobulin IgD or a variant thereof may consist of 30 or 49 amino acids. Additionally, the hinge region derived from immunoglobulin IgD or a variant thereof may contain at least one cysteine. In one embodiment, the hinge region derived from immunoglobulin IgD or a variant thereof has the following sequence: Arg Asn Thr Gly Arg Gly Gly Glu Glu Lys Lys Xaa1 Xaa2 Lys Glu Lys Glu Glu Gln Glu Glu Arg Glu Thr Lys Thr Pro Glu Cys Pro (SEQ ID NO: 17), where Xaa1 may be Lys or Gly and Xaa2 may be Glu, Gly, or Ser. Specifically, the hinge region derived from immunoglobulin IgD or a variant thereof may have the amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 19, thereby minimizing the occurrence of truncated forms during the protein production process.

[0025] In another embodiment, the hinge region derived from immunoglobulin IgD or a variant thereof has the following sequence: Ala Gln Pro Gln Ala Glu Gly Ser Leu Ala Lys Ala Thr Thr Ala Pro Ala Thr Thr Arg Asn Thr Gly Arg Gly Gly Glu Glu Lys Lys Xaa3 Xaa4 Lys Glu Lys Glu Glu Gln Glu Glu Arg Glu Thr Lys Thr Pro Glu Cys Pro (SEQ ID NO: 18), where Xaa3 may be Lys or Gly and Xaa4 may be Glu, Gly, or Ser. Specifically, the hinge region derived from immunoglobulin IgD or a variant thereof may have the amino acid sequence of SEQ ID NO: 4, thereby minimizing the occurrence of truncated forms during the protein production process.

[0026] In particular, in the hinge region derived from the immunoglobulin IgD having the sequence of SEQ ID NO: 4 or a variant thereof, at least one Thr may be glycosylated. Specifically, among the amino acids of SEQ ID NO: 18, Thr at position 13, 14, 18, or 19 may be glycosylated. It is preferred that all four Thr may be glycosylated. Glycosylation may be O-glycosylation.

[0027] The glycans attached to glycoprotein drugs are one of the main factors that determine their quality and play an important role in therapeutic efficacy, persistence in the body, targeting, immune response, etc. It has been confirmed that polypeptide dimers whose glycan ends are not terminated with sialic acid are immediately eliminated from the body.

[0028] The term "sialic acid" as used in the present invention may include N-acetylneuraminic acid (Neu5Ac) of formula 1 below and N-glycolylneuraminic acid (Neu5Gc) of formula 2 below.

[0029] [ka]

[0030] In this case, in one embodiment, the polypeptide dimer having a high content of sialic acid may have a high content of N-acetylneuraminic acid.

[0031] In addition, the sialic acid content of the polypeptide dimer can be increased by purification methods. In addition, the sialic acid content of the polypeptide dimer can be increased by producing the polypeptide dimer in a cell into which a sialic acid transferase gene has been introduced.

[0032] A polypeptide dimer having a high content of sialic acid may be characterized by a molar ratio of sialic acid / polypeptide dimer of 8 or more. For example, the molar ratio of sialic acid / polypeptide dimer in a polypeptide dimer having a high content of sialic acid may be 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30. Preferably, the molar ratio of sialic acid / polypeptide dimer in a polypeptide dimer having a high content of sialic acid may be 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25.

[0033] In certain embodiments, the molar ratio of sialic acid / polypeptide dimer in the polypeptide dimer having a high content of sialic acid may be at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, or at least 21. In addition, the molar ratio of sialic acid / polypeptide dimer in the polypeptide dimer having a high content of sialic acid may be 8 to 30 or 12 to 25. In addition, the molar ratio of sialic acid / polypeptide dimer in the polypeptide dimer having a high content of sialic acid may be 10 to 25, 11 to 24, or 12 to 23. In addition, the molar ratio of sialic acid / polypeptide dimer in the polypeptide dimer having a high content of sialic acid may be 13 to 22, 14 to 22, 15 to 22, 16 to 22, 17 to 22, 18 to 22, or 19 to 22. The sialic acid may be N-acetylneuraminic acid.

[0034] In addition, sialic acid can be attached to position 8 and the Fc region of a monomer comprising the extracellular domain of the alpha subunit of the IgE Fc receptor (FcεRIα-ECD). In this case, sialic acid can be attached to at least four or more of the above positions. Specifically, sialic acid can be attached to position 4, 5, 6, 7 or 8 of the monomer.

[0035] As described above, the polypeptide dimer having a high sialic acid content provided by the present invention may be in a form in which two monomers are bound to each other, and each monomer is obtained by the binding between the extracellular domain of the alpha subunit of the IgE Fc receptor and the modified Fc region. The polypeptide dimer having a high sialic acid content may be in a form in which the same two monomers are bound to each other by cysteines located at the hinge region. In addition, the polypeptide dimer having a high sialic acid content may be in a form in which two different monomers are bound to each other.

[0036] In this case, each polypeptide monomer may contain sialic acid at the same position, but may also contain sialic acid at different positions. In addition, when the molar ratio of sialic acid / polypeptide dimer is 8 or more, each monomer constituting the dimer may have a different molar ratio of sialic acid / polypeptide.

[0037] In addition, the polypeptide dimer may contain two different monomers. Specifically, one monomer may contain the extracellular domain of the alpha subunit of the IgE Fc receptor, and the other monomer may contain a fragment of the extracellular domain of the alpha subunit of the IgE Fc receptor. An embodiment of the monomer may consist of the amino acid sequence represented by SEQ ID NO:20, SEQ ID NO:21, or SEQ ID NO:22.

[0038] In addition, the polypeptide dimer having a high content of sialic acid provided by the present invention exhibits a binding affinity for IgE that is 10 to 100 times, 20 to 90 times, 20 to 70 times, 30 to 70 times, or 40 to 70 times higher than that of omalizumab (anti-IgE antibody), and preferably exhibits a binding affinity for IgE that is approximately 70 times higher than that of omalizumab.

[0039] In another aspect of the present invention, there is provided a pharmaceutical composition for preventing or treating an allergic disease, comprising a polypeptide dimer having a high content of sialic acid.

[0040] The polypeptide dimer is the same as above. In particular, the pharmaceutical composition may be characterized as being for subcutaneous injection. It has been confirmed that the polypeptide dimer having a high content of sialic acid is more effective in treating and / or preventing allergic diseases when injected subcutaneously than the polypeptide dimer having a low content of sialic acid.

[0041] As used herein, the term "allergic disease" refers to a pathological condition caused by an allergic reaction mediated by mast cell activation, such as mast cell degranulation. For example, such an allergic disease may be selected from the group consisting of, but not limited to, food allergy, atopic dermatitis, asthma, allergic rhinitis, allergic conjunctivitis, allergic dermatitis, chronic idiopathic urticaria, and allergic contact dermatitis. In particular, the allergic disease may be IgE-mediated.

[0042] In the pharmaceutical composition, the polypeptide dimer may be contained in any amount (effective amount) depending on the use, formulation, purpose of formulation, etc., as long as the polypeptide dimer can exhibit anti-allergic activity. A typical effective amount of the polypeptide dimer is determined within the range of 0.001% by weight to 20.0% by weight based on the total weight of the composition. The "effective amount" means an amount capable of inducing an anti-allergic effect. Such an effective amount can be determined by one skilled in the art.

[0043] The pharmaceutical composition may further contain a pharma- ceutically acceptable carrier. Specifically, the pharmaceutical composition contains a pharma- ceutically acceptable carrier and can be made into an oral or parenteral preparation according to the administration route by a conventional method known in the art.

[0044] In the case where the pharmaceutical composition of the present invention is made into an oral preparation, the pharmaceutical composition can be made into preparations, such as powder, granules, tablets, pills, sugar-coated tablets, capsules, liquids, gels, syrups, suspensions, and wafers, together with suitable carriers, by conventional methods known in the art.Suitable examples of pharmaceutically acceptable carriers can include sugars such as lactose, glucose, sucrose, dextrose, sorbitol, mannitol, and xylitol, starches such as corn starch, potato starch, and wheat starch, celluloses such as methylcellulose, ethylcellulose, sodium carboxymethylcellulose, and hydroxypropylmethylcellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, magnesium stearate, mineral oil, malt, gelatin, talc, polyols, vegetable oils, etc. When made into a preparation, the preparation can be carried out, if necessary, by including diluents and / or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants.

[0045] When the pharmaceutical composition of the present invention is made into a parenteral preparation, the pharmaceutical composition can be made into the form of injection, transdermal agent, nasal inhalant, and suppository by a conventional method known in the art together with a suitable carrier.When it is made into an injection, sterilized water, ethanol, polyol, such as glycerol and propylene glycol, or a mixture thereof, can be used as a suitable carrier.As for the carrier, it is preferable to use an isotonic solution, such as Ringer's solution, triethanolamine-containing phosphate buffered saline (PBS), sterilized water for injection, and 5% dextrose, etc.

[0046] Preparation of pharmaceutical compositions is known in the art, and specifically, Remington's Pharmaceutical Sciences (19th ed., 1995), etc. may be referred to.

[0047] The preferred daily dose of the pharmaceutical composition of the present invention is in the range of 0.01 μg / kg to 10 g / kg, preferably 0.01 mg / kg to 1 g / kg, depending on the patient's condition, body weight, sex, age, severity of the disease, or route of administration. The pharmaceutical composition may be administered once a day or, in higher doses, several times a day.

[0048] The subject to which the composition of the present invention can be applied (prescribed) is a mammal, for example, may be a human, a dog, or a cat, and is particularly preferably, but not limited to, a human. The pharmaceutical composition may further contain any compound or natural extract whose safety has already been confirmed and which is known to have antiallergic activity, for the purpose of enhancing and strengthening the antiallergic activity.

[0049] The present inventors have conducted research to develop a safe and effective therapeutic agent for allergic diseases. As a result, it was confirmed that a polypeptide dimer having a high content of sialic acid has superior binding affinity with IgE compared to a polypeptide dimer having a low content of sialic acid (Table 3). In addition, it was confirmed that when a polypeptide dimer having a high content of sialic acid is subcutaneously administered to a subject suffering from an allergic disease, the concentrations of IgE and MCPT-1 in the blood are effectively reduced compared to a polypeptide dimer having a low content of sialic acid, and the effect persists even after a specified time has elapsed (Figures 13 and 14).

[0050] Thus, in another aspect of the present invention, there is provided a transdermal patch comprising the pharmaceutical composition. Additionally, in another aspect of the present invention, there is provided a topical patch comprising the pharmaceutical composition.

[0051] In another aspect of the present invention, there is provided a food composition for improving or alleviating allergic symptoms, comprising a polypeptide dimer having a high content of sialic acid.

[0052] The polypeptide dimer having a high content of sialic acid is the same as above. In addition, the polypeptide dimer having a high content of sialic acid may be bound to a suitable delivery means for efficient delivery to the intestine.

[0053] In addition, the food compositions may be prepared in any form, such as beverages, e.g., tea, juice, carbonated drinks, and electrolyte drinks, processed dairy products, e.g., milk and yogurt, health functional food preparations, e.g., tablets, capsules, pills, granules, liquids, powders, flakes, pastes, syrups, gels, jellies, and bars.

[0054] The food composition may fall within any product category in legal or functional classification, as long as it complies with the enforcement regulations at the time of manufacture and distribution. For example, the food composition may be a health functional food under the Health Functional Food Law, or may fall within the scope of confectionery, beans, tea, beverages, food for special dietary use, etc., according to each food type in the food code of the Food Sanitation Law (standards and specifications of food notified by the Food and Drug Administration). For other food additives that may be contained in the food composition of the present invention, reference may be made to the food code or food additive code under the Food Sanitation Law.

[0055] In another aspect of the present invention, there is provided a method for treating or preventing an allergic disease, comprising administering to a subject a polypeptide dimer having a high sialic acid content. The polypeptide dimer having a high sialic acid content is the same as described above.

[0056] The subject may be a mammal, preferably a human, dog or cat. Administration may be accomplished orally or parenterally. Parenteral administration may be by methods such as subcutaneous, intravenous, mucosal and intramuscular administration.

[0057] The allergic disease may be selected from the group consisting of food allergy, atopic dermatitis, asthma, allergic rhinitis, allergic conjunctivitis, allergic dermatitis, chronic idiopathic urticaria, and allergic contact dermatitis.

[0058] In another aspect of the present invention, there is provided a use of a polypeptide dimer having a high content of sialic acid for preventing or treating an allergic disease.

[0059] The present invention will now be described in more detail with reference to the following examples. However, the following examples are intended to only illustrate the present invention, and the scope of the present invention is not limited thereto.

[0060] Example 1 Preparation of a polypeptide containing FcεRIα-ECD and an Fc region A C-terminally modified polypeptide of the extracellular domain of the alpha subunit of the IgE Fc receptor (FcεRIα-ECD) was prepared according to the method disclosed in US Pat. No. 7,867,491.

[0061] First, to express the proteins (FcεRIαECD-Fc1), (FcεRIαECD-Fc2), and (FcεRIαECD-Fc3) (the extracellular domain of the α chain of FcεRI having the amino acid sequence of SEQ ID NO: 1 and the modified immunoglobulin Fc of SEQ ID NO: 2 are linked via the hinge of SEQ ID NO: 19, the hinge of SEQ ID NO: 3, and the hinge of SEQ ID NO: 4, respectively), the cassettes obtained by linking the genes encoding each protein were cloned into the pAD15 vector (Genexin, Inc.) to construct the FcεRIαECD-Fc protein expression vector. Next, each expression vector was transduced into CHO DG44 cells (from Dr. Chasin, Columbia University, USA).

[0062] At the time of transfection into the cell lines, expression vectors obtained by cloning the α-2,6-sialic acid transferase gene into the pCI Hygro vector (Invitrogen) are simultaneously transfected to separately prepare cell lines capable of expressing FcεRIαECD-Fc2ST and FcεRIαECD-Fc3ST proteins, to which sialic acid is added.

[0063] As a primary screening procedure, HT selection was performed using 5-hydroxytryptamine (HT)-free 10% dFBS medium (Gibco, USA, 30067-334), MEMα medium (Gibco, 12561, USA, Cat. No. 12561-049), and HT+ medium (Gibco, USA, 11067-030). Then, methotrexate (MTX) amplification was performed with HT-selected clones to amplify productivity using the dihydrofolate reductase (DHFR) system.

[0064] After completion of MTX amplification, subculture was performed approximately 1 to 5 times for cell stabilization for the purpose of evaluating productivity. Then, the unit productivity of the MTX-amplified cells was evaluated. The results are shown in Table 1 below.

[0065] [Table 1]

[0066] As shown in Table 1, the FcεRIαECD-Fc3 cell line showed a cytotoxicity of 16.9 μg / 10 after methotrexate amplification at 2 uM. 6 On the other hand, the FcεRIαECD-Fc3 cell line co-transfected with 2,6-sialic acid transferase (FcεRIαECD-Fc3ST) showed a 10.2μg / 10 6 In addition, the FcεRIαECD-Fc2 cell line showed a 20.9μg / 10 6In addition, the FcεRIαECD-Fc2 cell line co-transfected with 2,6-sialic acid transferase (FcεRIαECD-Fc2ST) produced 25.1 μg / 10 mAb after methotrexate amplification at 0.1 μM. 6 The productivity of the cells was demonstrated: the FcεRIαECD-Fc2 cell line co-transfected with 2,6-sialic acid transferase (selected under 0.1 uM methotrexate amplification conditions) was identified as exhibiting the highest productivity.

[0067] The polypeptide produced from the FcεRIαECD-Fc2 cell line (FcεRIαECD-Fc) is referred to as "FcεRIαECD-Fc2" and the polypeptide produced from the FcεRIαECD-Fc2+a2,6-ST cell line is referred to as "FcεRIαECD-Fc2ST". In addition, the polypeptide produced from the FcεRIαECD-Fc3 cell line is referred to as "FcεRIαECD-Fc3" and the polypeptide produced from the FcεRIαECD-Fc3+a2,6-ST cell line is referred to as "FcεRIαECD-Fc3ST".

[0068] Example 2 Purification of polypeptide (FcεRIαECD-Fc) and confirmation of purity Among the cell lines selected in Example 1 above, i) FcεRIαECD-Fc3 cell line, ii) FcεRIαECD-Fc3+a2,6-ST cell line, and iii) FcεRIαECD-Fc2+a2,6-ST cell line were cultured at a 60 ml scale by batch culture. The resulting culture was purified using a protein A affinity column to obtain FcεRIαECD-Fc, and the purified FcεRIα ECD-Fc was then subjected to SE-HPLC (size-exclusion high performance liquid chromatography) and SDS-PAGE to identify the purity of the polypeptide.

[0069] Specifically, SDS-PAGE was performed under non-reducing conditions. Under non-reducing conditions, each purified polypeptide was mixed with a non-reducing sample buffer, and then electrophoresis was performed for 30 minutes on a Mini-Protean TGX™ gel.TM The electrophoresis was performed using a Bio-Rad gel (Tris-Glycine-SDS) buffer at 200 V. After electrophoresis, the proteins were stained with Coomassie Brilliant Blue solution. The results are shown in Table 2 and Figure 1.

[0070] [Table 2]

[0071] As shown in Table 2 above, the purity of each polypeptide purified by SE-HPLC was confirmed to be 93% or more. It was confirmed that impurities, such as truncated forms, did not appear under non-reducing conditions, and in particular, the purity was 93% or more, and there were no impurities even after the thawing / freezing process.

[0072] Experimental Example 1 Confirmation of dimer formation of polypeptide (FcεRIαECD-Fc) Among the cell lines selected in Example 1 above, i) FcεRIαECD-Fc3 cell line, ii) FcεRIαECD-Fc3+a2,6-ST cell line, and iii) FcεRIαECD-Fc2+a2,6-ST cell line were cultured at a 60 ml scale by batch culture. Then, SE-HPLC and SDS-PAGE were performed on the culture supernatant and the purified product obtained from the purification of the polypeptide using a protein A affinity column. In this case, they were performed on the culture supernatant and the product purified under non-reducing and reducing conditions, respectively.

[0073] Non-reducing conditions were performed in the same manner as in Example 2. Meanwhile, under reducing conditions, each purified polypeptide was mixed with reducing sample buffer containing 2-mercaptoethanol, and then denatured at a temperature of 100°C for 5 minutes. Then, electrophoresis was performed in a Mini Protean TGX™ Gel (Bio-Rad) with TGS buffer at 200V for 30 minutes. After electrophoresis, the proteins were stained with Coomassie Brilliant Blue solution.

[0074] As a result, a polypeptide having a size of about 150 kDa was detected under non-reducing conditions, and a polypeptide having a size of about 75 kDa was detected under reducing conditions. This confirmed that the polypeptide formed a dimer (Figure 2). In particular, it was confirmed that the purity of the polypeptide dimer was high even in the culture supernatant corresponding to the input, and that the polypeptide was not detected in the sample obtained by passing the culture supernatant through the affinity column (FT; flow-through), but the polypeptide was detected in the eluted sample. In addition, due to the low pH of the eluted sample, no significant difference was observed even when the sample (Elution_N) that was immediately neutralized with 1 M Tris buffer (pH 9.0) was compared with the sample that was not neutralized (Elution) (Figure 2).

[0075] In addition, it was determined that not only was the polypeptide purified to a very high degree of purity (98% or higher), but that the polypeptide was also expressed to a very high degree of purity even in the culture supernatant, indicating that the process development steps could be simplified to develop the polypeptide expressed in the cell line of interest into a medical product, thus greatly reducing the cost of medical product development.

[0076] Experimental Example 2 Confirmation of the binding affinity of polypeptide dimers to IgE The binding affinity to IgE was measured in comparison with the purified products obtained by purifying the polypeptides produced in Example 1, i) FcεRIαECD-Fc2, ii) FcεRIαECD-Fc2ST, iii) FcεRIαECD-Fc3, and iv) FcεRIαECD-Fc3ST by the method of Example 2 above, and the commercially available anti-IgE antibody, omalizumab (trade name: Xolair).

[0077] Specifically, the binding affinity to IgE was measured by coating IgE onto the channel of a protein GLC sensor chip (Bio-Rad Laboratories, Inc., Cat. No. 176-5011) and flowing omalizumab or each FcεR1αECD-Fc protein at various concentrations at a rate of 30 μL per minute. The experiment was performed by determining the zero base using 25 mM NaOH as the regeneration buffer and then repeating the above steps. After that, the binding curve was determined using a protein binding analyzer (ProteOn XPR36, Bio-Rad Laboratories, Inc., USA). The results are shown in Table 3.

[0078] [Table 3]

[0079] As shown in Table 3, the association rate (ka) values ​​of the polypeptide dimer according to the embodiment of the present invention with IgE were measured to be 1.5-2.0 times lower than that of omalizumab. That is, its binding affinity to substances other than IgE was found to be 1.5-2.0 times lower than that of omalizumab. In addition, the dissociation rate (kd) values ​​of the polypeptide dimer according to the embodiment of the present invention were measured to be 40-106 times higher than that of omalizumab. As a result, the polypeptide dimer according to the embodiment of the present invention has an equilibrium dissociation constant (KD) that is 22-69 times higher than that of omalizumab. <kd ka>) values. From this, it was determined that the polypeptide dimers according to the embodiments of the present invention have significantly increased binding affinity for IgE compared to omalizumab. In particular, it was determined that the polypeptide dimer with added sialic acid (FcεRIαECD-Fc2ST) exhibited the highest IgE binding affinity, 69-fold higher than omalizumab.

[0080] In addition, as shown in Figures 3 and 4, after a certain period of time has elapsed after binding, omalizumab loses its binding to IgE, while the polypeptide dimer according to an embodiment of the present invention (FcεRIαECD-Fc2ST, IgE TRAP It was confirmed that once bound to IgE, the polypeptide dimer does not dissociate from IgE. In other words, it was confirmed that the polypeptide dimer according to the embodiment of the present invention does not easily dissociate from IgE and has a better ability to maintain the bound state than omalizumab.

[0081] Experimental Example 3 Confirmation of the binding affinity of the polypeptide dimer to the IgG receptor The polypeptide dimer according to the embodiment of the present invention (FcεRIαECD-Fc2ST, IgE TRAP The binding affinity of rifapril (Rafenib) or omalizumab (Xolair) was confirmed using the Octet RED384 system (Pall ForteBio, CA, USA).

[0082] Specifically, Fc gamma receptors FcγRI, FcγRIIA, FcγRIIB, FcγRIIIA, and FcγRIIIB recombinant proteins (R&D Systems Inc., 5 μg / ml) were immobilized on an activated AR2G biosensor in 300 mM acetate buffer (pH 5). PBS containing 0.1% Tween-20 and 1% bovine serum was used as the running buffer. All measurements were performed at 30°C using a sample plate shaker at a speed of 1,000 rpm. The results are shown in Figures 5a-5e, and the binding affinity of omalizumab and the polypeptide dimer to the IgG Fc gamma receptor was quantified and shown in Figure 6.

[0083] As a result, it was confirmed that Omalizumab exhibits high binding affinity to the Fc gamma receptor of IgG, while the polypeptide dimer has a significantly lower binding affinity to the Fc gamma receptor of IgG, and thus, it was confirmed that the polypeptide dimer does not bind to the Fc gamma receptor of IgG.

[0084] Experimental Example 4 Confirmation of the activity of the polypeptide dimer by beta-hexosaminidase assay in mouse bone marrow-derived mast cells A beta-hexosaminidase assay was performed for in vitro activity analysis of polypeptide dimers according to embodiments of the present invention.

[0085] Specifically, the polypeptide dimer (FcεRIαECD-Fc2) according to the embodiment of the present invention was mixed with IgE (1 μg / mL) at various concentrations and incubated for 30 minutes at 20° C. to prepare samples. Mouse bone marrow-derived mast cells in culture for mast cell activation were washed with Hank's balanced salt solution (HBSS) buffer to remove the medium, the number of cells was measured, and then 5×10 5 The cells were resuspended in 40 μL of HBSS buffer.

[0086] 50 μL of the sample thus prepared was added to the activated mast cells. The resultant was then incubated for 30 minutes at 37° C. in a 5% CO2 incubator. After the addition of 10 μL each of the foreign antigen DNP (2,4-dinitrophenol, 100 ng / mL), the incubation was again carried out for 30 minutes at 37° C. in 5% CO2, and then 30 μL of the supernatant was separated.

[0087] 30 μL of the separated supernatant and 30 μL of substrate (4-nitrophenyl N-acetyl-β-D-glucosaminide, 5.84 mM) were thoroughly mixed and then incubated at 37° C. for 20 minutes in 5% CO2. Then, 140 μL of 0.1 M sodium carbonate buffer (pH 10) was added as a stop solution to terminate the reaction. After that, the absorbance was measured at 405 nm to determine the amount of β-hexosaminidase secreted by foreign antigens in activated mast cells. The results are shown in FIG. 7.

[0088] As shown in Figure 7, it was confirmed that the activity of IgE was significantly inhibited when the concentration of IgE and the polypeptide dimer of the present invention was 1:1. That is, it was confirmed that the polypeptide dimer according to the embodiment of the present invention reacts even when its concentration is the same as that of IgE.

[0089] Experimental Example 5 Comparison of the activity of polypeptide dimers and human anti-IgE antibodies using β-hexosaminidase assay in human FcεRI-expressing mouse bone marrow-derived mast cells The polypeptide dimer according to the embodiment of the present invention (FcεRIαECD-Fc2ST, IgE TRAP A beta-hexosaminidase assay was performed to compare the activity of IFN-γ-γ and the human anti-IgE antibody Xolair (omalizumab).

[0090] Each of the polypeptide dimers and Xolair was prepared to various concentrations and then mixed with human IgE (1 μg / mL). The samples were then incubated at room temperature for 30 minutes to prepare samples. In addition, differentiated mast cells were prepared from mouse bone marrow into which the human FcεRI gene had been introduced and the mouse FcεRI gene had been removed. The prepared mast cells were washed with HBSS buffer and then diluted with 5×10 5 The cells were resuspended in 60 μL of HBSS buffer.

[0091] Then, 20 μL of the sample thus prepared was added to the mast cells, which were then incubated at 37° C. in a 5% CO2 incubator for 30 minutes. Then, 20 μL of human anti-IgE antibody (BioLegend, Cat. No. 325502, 0.5 μg / mL) was added, after which the result was incubated again at 37° C. in a 5% CO2 incubator for 30 minutes. Then, 30 μL of the supernatant was separated after centrifugation at 1,500 rpm at 4° C. 30 μL of the separated supernatant and 30 μL of substrate (4-nitrophenyl N-acetyl-β-glucosaminide, 5.84 mM) were thoroughly mixed, which were then incubated at 37° C. in a 5% CO2 incubator for 25 minutes. Then, 140 μL of 0.1 M sodium carbonate buffer (pH 10) was added to terminate the reaction. The absorbance was then measured at 405 nm to compare the relative amounts of secreted β-hexosaminidase to determine the inhibitory effect on mast cells according to each concentration of the samples. The results are shown in Figure 8.

[0092] As shown in Figure 8, IC 50 was measured at approximately 11.16 ng / mL, and the IC 50 was measured to be approximately 649.8 ng / mL. Thus, the polypeptide dimer was identified as having 58-fold greater inhibitory potency against mast cell activity than Xolair.

[0093] Experimental Example 6 Confirmation of activity of polypeptide dimer by in vivo assay in food allergy model Balb / c mice (Orientbio Inc.) were intraperitoneally administered 50 μg of ovalbumin (OVA) and 1 mg of alum twice at 14-day intervals to induce sensitization, followed by oral administration of 50 mg of OVA five times on days 28, 30, 32, 34, and 36 to induce food allergy in the intestine.

[0094] After two oral doses of OVA, i.e., on day 31, the mice were divided into three groups containing seven mice each: group 1 received a high concentration (200 μg) of the polypeptide dimer (FcεRIαECD-Fc2ST), group 2 received a low concentration (20 μg) of the polypeptide dimer (FcεRIαECD-Fc2ST), and group 3 received nothing.

[0095] During oral administration of OVA, we observed whether diarrhea occurred due to the induction of food allergy. In addition, mice were euthanized on day 37 and the number of mast cells in the small intestine, IgE concentration in the blood, and mast cell degranulation enzyme (mast cell protease 1 (MCPT-1)) concentration in the blood were analyzed for mice belonging to each group.

[0096] As a result, as shown in Figure 9, diarrhea occurred in the mice of group 3 after the second oral administration of OVA. On the other hand, diarrhea occurred in the mice of groups 1 and 2 after the third oral administration of OVA. Notably, the frequency of diarrhea in the mice of group 1 was lower than that in the mice of group 2. This confirmed that the effect on food allergy increased in proportion to the concentration of the polypeptide dimer.

[0097] Experimental Example 7 Analysis of sialic acid content of polypeptide dimers Based on the fact that the polypeptide produced from the FcεRIαECD-Fc2+a2,6-ST cell line prepared in Example 1 above had the highest production rate and that the polypeptide dimer (FcεRIαECD-Fc2ST) in Experimental Examples 4 to 6 had an excellent anti-allergic effect, the sialic acid content of the polypeptide dimer was analyzed to investigate the anti-allergic efficacy of the polypeptide dimer depending on the sialic acid content.

[0098] Specifically, to measure the sialic acid content contained in the glycan structure of the polypeptide dimer (FcεRIαECD-Fc2ST) produced from the FcεRIαECD-Fc2+a2,6-ST cell line prepared in Example 1 above, sialic acid was first separated by treating it with sialidase, an enzyme involved in the catabolism of sialic acid. The separated sialic acid was then isolated, detected, and quantified using HPLC (Waters, Alliance e2659).

[0099] The polypeptide dimer was separated into three samples according to the pH gradient, isolated and purified. The three samples were placed in an AmiconUltra 10K (Millipore, UFC501096) filter, centrifuged for 10 minutes at 13,000 rpm and 4°C, and concentrated five times by exchanging the concentrate with deionized water. The concentration of the sample was set to 10 mg / mL or more when measured at a wavelength of 280 nm.

[0100] Then, 0.5 mg of each sample was taken and placed in an EP tube, and 1 μL of sialidase (Roche, 10 269 611 001) and 40 μL of sodium phosphate buffer (pH 7.0) were added at a concentration of 10 mM, followed by deionized water to a final volume of 100 μL. 2 μL of each sample was taken and the concentration was measured at a wavelength of 280 nm, and the confirmed concentration value was used as the final analytical concentration.

[0101] The samples were reacted for 18 hours in a 37° C. incubator, then placed in an AmiconUltra 10K filter and centrifuged at 13,000 rpm and 4° C. for 15 minutes, and the filtrate passed through the filter was used for analysis. The HPLC analysis conditions are shown in Table 4 below.

[0102] [Table 4]

[0103] The standard substance for calculating the content of sialic acid is a mixture of N-acetylneuraminic acid (hereinafter referred to as NANA) and N-glycolylneuraminic acid (hereinafter referred to as NGNA). A linear regression equation for the standard curve was obtained to calculate the molar concentrations of NGNA and NANA in the analyte. The mixture used is shown in Table 5 below.

[0104] [Table 5]

[0105] The NANA sialic acid content in the samples was calculated using the NANA content and expressed as the molar ratio of sialic acid / sample (mol / mol).

[0106] [Equation 1] Sialic acid content of sample = (molar concentration of NANA in sample) / (molar concentration of sample)

[0107] In addition, the content of NGNA in the samples was calculated using the NGNA content, which was expressed as the molar ratio of NGNA / analyte (mol / mol).

[0108] [Equation 2] NGNA content of sample = (molar concentration of NGNA in analyte) / (molar concentration of analyte)

[0109] The results are shown in Table 6 below.

[0110] [Table 6]

[0111] As shown in Table 6, three samples were separated according to the pH gradient, separated, purified, and the sialic acid content in each sample was measured separately. To compare the anti-allergic efficacy according to the sialic acid content, the polypeptide dimers were classified into "SA low ", "SA medi " and "SA high "It is called "

[0112] Experimental Example 8 Confirmation of changes in polypeptide dimer formation depending on sialic acid content To confirm whether there is a change in the dimer formation of the polypeptide depending on the sialic acid content, the SA isolated in Example 9 was low , S.A. medi and S.A. high was subjected to SDS-PAGE analysis under non-reducing and reducing conditions in the same manner as in Experimental Example 1.

[0113] As a result, S.A. low , S.A. medi and S.A. high In all of the above, a polypeptide having a size of about 150 kDa was detected under non-reducing conditions, and a polypeptide having a size of about 75 kDa was detected under reducing conditions, confirming that the polypeptides formed dimers (Figure 10).

[0114] Experimental Example 9 Confirmation of the isoelectric point of polypeptide dimers according to sialic acid content To confirm whether the isoelectric point of the polypeptide dimer changes depending on the sialic acid content, the SA isolated in Experiment 7 was low , S.A. medi and S.A. high was mixed with IEF sample solution, then loaded onto a pH 3-7 IEF gel (Invitrogen), and electrophoresis was performed at 100 V for 1 hour, 200 V for 1 hour, and 500 V for 30 minutes, sequentially. After electrophoresis was completed, the gel was reacted in a fixative solution containing 12% trichloroacetic acid and 3.5% sulfosalicylic acid for 30 minutes, and then washed with distilled water. Proteins were stained with Coomassie Brilliant Blue solution.

[0115] As a result, S.A. low , S.A. medi and S.A. high The isoelectric points of the sialic acid derivatives were found to vary slightly depending on the sialic acid content, being approximately 5.3, 4.9, and 4.7, respectively (FIG. 11).

[0116] Experimental Example 10: Confirmation of antiallergic activity of polypeptide dimers according to sialic acid content in food allergy animal models: Measurement of diarrhea frequency To determine whether the activity of the polypeptide dimers varies depending on the sialic acid content, sensitization was induced in Balb / c mice (Orient Bio) by intraperitoneal administration of 50 μg OVA and 1 mg alum twice at 14-day intervals. Food allergy was then induced by oral administration of 50 mg OVA seven times over days 28, 30, 32, 34, 36, 38, and 40. In this case, oral administration of OVA was performed after a 4-hour fast.

[0117] OVA was orally administered twice, and then on day 40, the mice were divided into three groups of seven mice each. high Group 1 was a group in which a high concentration (200 μg) of a polypeptide dimer with a low content of sialic acid (SA low Mice were divided into group 2, in which OVA was administered subcutaneously at a high concentration (200 μg), and group 3, in which PBS was administered subcutaneously. We examined whether diarrhea would occur due to the induction of food allergy when OVA was orally administered.

[0118] As a result, diarrhea occurred in mice of group 3 after the fourth oral administration of OVA. Diarrhea occurred in mice of group 2 after the fifth oral administration of OVA. Notably, the frequency of diarrhea immediately increased in mice of group 2 after the sixth oral administration of OVA. On the other hand, diarrhea occurred in mice of group 1 after the sixth oral administration of OVA, but the frequency of diarrhea was maintained and did not increase in mice of group 1 even after the seventh oral administration of OVA (Figure 12). This suggests that the high content of sialic acid in polypeptide dimers (SA high ) is a polypeptide dimer with a low content of sialic acid (SA low ) and was confirmed to have superior anti-allergic effects.

[0119] Experimental Example 11: Confirmation of anti-allergic activity of polypeptide dimers according to sialic acid content in food allergy animal models: Measurement of IgE concentration in blood Blood was collected from each group of mice that had received the seventh oral administration of OVA in Experimental Example 10 by retro-orbital sampling. After 30 minutes of reaction at ambient temperature, serum was separated by centrifugation at 13,000 rpm for 15 minutes at 4° C. To measure the free IgE concentration in blood, a mouse total IgE ELISA kit (BioLegend) was used, where the ELISA was performed according to the manufacturer's protocol, except that the polypeptide dimer (SA) according to an embodiment of the present invention was not used. low and S.A. high ) was used as a coating material for 96-well plates in place of anti-IgE antibody.

[0120] Specifically, a 96-well plate was filled with a polypeptide dimer (SA low and S.A. high ) and reacted overnight at 4°C. The next day, after washing with PBS containing 0.05% Tween 20 (hereinafter referred to as washing buffer), blocking buffer (assay diluent) was added and reacted for 1 hour. After washing with washing buffer, mouse IgE and mouse serum samples used as standard solutions were diluted with 1X assay diluent, placed on the plate, and reacted for 2 hours.

[0121] After washing again with washing buffer, biotin-labeled mouse anti-IgE antibody was added and reacted for 1 hour. After washing with washing buffer, HRP (horseradish peroxidase)-labeled avidin (avidin-HRP) was added and reacted for 30 minutes. After washing with washing buffer, substrate solution was added and reacted for 20 minutes, during which time light was blocked, and then stop solution (1M H2SO4) was added to stop the reaction. After that, absorbance values ​​were measured at a wavelength of 450 nm using a microplate reader (Epoch microplate spectrophotometer), and concentrations were calculated.

[0122] As a result, the IgE concentration in the blood of mice in group 3 that received PBS subcutaneously was calculated to be about 8,000 ng / mL. In addition, the IgE concentration in the blood of mice in group 3 that received PBS subcutaneously was calculated to be about 8,000 ng / mL. low For mice in group 2 that received subcutaneous administration of sialic acid-rich polypeptide dimer (SA), the IgE concentration in the blood was calculated to be about 7,000 ng / mL. high For mice in group 1 that received subcutaneous administration of 1, the IgE concentration in the blood was calculated to be approximately 4,900 ng / mL, and there was a significant difference in the IgE concentration values ​​in the blood between mice in groups 2 and 3 (Figure 13).

[0123] From these results, it was found that the IgE content in the blood was reduced when the polypeptide dimer having a high content of sialic acid was administered subcutaneously. In addition, based on such a reduction in IgE in the blood, it was predicted that the polypeptide dimer having a high content of sialic acid would be effective in treating allergies.

[0124] Experimental Example 12 Confirmation of anti-allergic activity of polypeptide dimers according to sialic acid content in food allergy animal models: Measurement of MCPT-1 concentration in blood Serum was prepared by drawing blood from mice in each group 2 days after the food allergy experiment was completed. To measure MCPT-1 (mast cell protease-1) concentrations in blood, an MCPT-1 ELISA kit (Invitrogen) was used according to the manufacturer's protocol.

[0125] Specifically, a 96-well immunization plate was coated with mouse anti-MCPT-1 antibody and reacted overnight at 4°C. The next day, after washing with PBS containing 0.05% Tween 20 (hereinafter referred to as washing buffer), PBS containing 1% BSA (bovine serum albumin) (hereinafter referred to as blocking buffer, assay diluent) was added and reacted for 1 hour. After washing with washing buffer, MCPT-1 and mouse serum samples used as standard solutions were diluted with 1X assay diluent, placed on the plate, and reacted for 2 hours.

[0126] After 2 hours, biotin-labeled mouse anti-MCPT-1 antibody was added and reacted for 1 hour. After washing with washing buffer, HRP (horseradish peroxidase)-labeled avidin (avidin-HRP) was added and reacted for 30 minutes. After washing with washing buffer, substrate solution was added and reacted for 20 minutes, during which time light was blocked, and then stop solution (1M H2SO4) was added to stop the reaction. After that, the absorbance value measured at a wavelength of 570 nm was subtracted from the absorbance value measured at a wavelength of 450 nm, and the absorbance value was determined using a microplate reader (Epoch microplate spectrophotometer) to calculate the concentration.

[0127] As a result, the blood MCPT-1 concentration was calculated to be about 4,000 ng / mL for mice in group 3 subcutaneously administered with PBS. In addition, the amount of MCPT-1 in the blood was about 4,000 ng / mL. low For mice in group 2 that received subcutaneous administration of MCPT-1, the blood concentration of MCPT-1 was calculated to be about 4,200 ng / mL. high For mice in group 1 that received subcutaneous administration of MCPT-1, the blood MCPT-1 concentration was calculated to be approximately 2,800 ng / mL, and there was a significant difference in the blood MCPT-1 concentration values ​​between mice in groups 2 and 3 (Figure 14).

[0128] Example 3 Preparation of a Polypeptide Dimer with High Sialic Acid Content by Purification To confirm the physical properties of the polypeptide dimers depending on the sialic acid content, polypeptide dimers containing a wide range of sialic acids were obtained from the FcεRIαECD-Fc2+a2,6-ST cell line and purified using affinity chromatography and anion exchange chromatography.

[0129] First, the cell culture fluid was subjected to affinity chromatography to remove the major impurities from the culture fluid. The affinity chromatography was performed using an Amsphere™ A3 prepacked column (5 cm bed height, 5 mL volume) packed with Amsphere™ A3 resin and an AKTA Avant 25 instrument liquid chromatography system. The affinity chromatography was performed using 100 mM glycine pH 3.3 as the elution buffer.

[0130] Anion exchange chromatography was then performed using a liquid chromatography system with a Hiscreen QFF (bed height 10 cm, volume 5 mL) packed with Q Sepharose Fast Flow resin and an AKTA Avant 25 instrument. 20 mM phospho-citrate pH 3.5 was used as the elution buffer. In this case, phospho-citrate pH 4.0 with a concentration of 20 mM was adjusted as the washing buffer to obtain dimers with various sialic acid contents. The analysis of the sialic acid content was performed by the analysis method used in Experimental Example 7. As a result, polypeptide dimers with sialic acid contents of 7.0 mol / mol, 10.3 mol / mol, 12.9 mol / mol, 14.9 mol / mol and 21.4 mol / mol were obtained.

[0131] Experimental Example 13 Pharmacokinetic analysis of polypeptide dimers according to sialic acid content in a mouse model To perform pharmacokinetic analysis according to the sialic acid content of the polypeptide dimer, the polypeptide dimers having sialic acid contents of 7.0 mol / mol, 10.3 mol / mol, 12.9 mol / mol, 14.9 mol / mol and 21.4 mol / mol prepared in Example 3 were subcutaneously injected into mice at a concentration of 10 mg / kg, respectively. To analyze the pharmacokinetics of the polypeptide dimer, blood was collected at 0 hours, 3 hours, 10 hours, 24 hours, 72 hours, 168 hours and 240 hours after administration of the substance and analyzed in the following manner:

[0132] Anti-FcεRI antibody (Invitrogen) was diluted to a concentration of 0.5 μg / mL with 1X PBS (Welgene), added to an immunoplate (Thermo), and reacted overnight at 4°C. After the reaction was completed, the immunoplate was washed with 1X PBST, and a blocking solution, I-Block solution (Invitrogen), was added to each well and reacted at ambient temperature for 1 hour. During blocking, standards and analytical samples were prepared. The polypeptide dimer was diluted with 1% BSA / PBS containing mouse blank serum to a concentration of 0.19 ng / mL to 200 ng / mL to prepare a standard substance, and was also diluted 1 / 20 to 1 / 300 with 1% BSA / PBS containing blank serum to prepare an analytical sample.

[0133] After blocking was completed, the plate was washed with 1X PBST, and the prepared standards and analytical samples were added per well, and then reacted at ambient temperature for 1 hour. After that, the plate was washed with 1X PBST, and anti-human IgG4-HRP (Southern biotech) diluted 1:10,000 was added, and then reacted at ambient temperature for 1 hour. After the reaction was completed, the plate was washed with 1X PBST, and TMB solution (Thermo) was added to the wells and reacted. When the absorbance value was measured in the range of 0.8 to 1.0 at a wavelength of 650 nm using a microplate reader (Molecular devices), a stop solution (Sigma) was added per well to stop the reaction. After the reaction was terminated, the absorbance was measured on the plate at a wavelength of 450 nm within 5 minutes, and the values ​​were analyzed. The obtained pharmacokinetic graph and pharmacokinetic parameters of the polypeptide dimer according to the sialic acid content are shown in Figure 15 and Table 7.

[0134] As a result, as shown in Table 7, it was confirmed that the higher the sialic acid content of the polypeptide dimer administered to the mice, the higher the concentration in the blood.

[0135] [Table 7]

[0136] Experimental Example 14: Confirmation of efficacy according to sialic acid content of polypeptide dimers in a mouse model of passive systemic anaphylaxis In order to confirm the difference in the in vivo anti-allergic effect depending on the sialic acid content of the polypeptide dimer, a method disclosed in a literature was applied to induce passive systemic anaphylaxis (PSA) in mice in the following manner (Methods and Protocols, Methods in Molecular Biology, vol. 1032, DOI 10.1007 / 978-1-62703-496-8_10). It is known that mast cells are activated by the induction of anaphylaxis, and body temperature decreases by increasing mast cells. Using this, while inducing PSA in mice, polypeptide dimers having each sialic acid content were administered, and then body temperature was measured to compare the anti-allergic effect.

[0137] The body temperature of transponder-inserted Balb / c mice (Orient Bio) was measured, then 20 μg of anti-DNP IgE (Sigma) in 0.9% NaCl was administered intraperitoneally, followed by subcutaneous administration of polypeptide dimers with different sialic acid contents at 10 mg / kg. After 24 hours, the body temperature of the mice was measured before administration of DNP-HAS (Sigma) in 0.9% NaCl, a foreign antigen. Then, 1 mg of antigen was administered intravenously. After administration, the body temperature of the mice was measured at 10-minute intervals for 1 hour using a remote thermometer (Bio Intermediate Data Systems). The experimental results are shown in FIG. 16.

[0138] As a result, it was confirmed that the body temperature of mice was decreased in the groups administered with the vehicle and the polypeptide dimer having a sialic acid content of 10.3 mol / mol, and the body temperature of mice was not decreased in the groups administered with the polypeptide dimer having a sialic acid content of 14.9 mol / mol or more, thereby confirming that the polypeptide dimer having a high sialic acid content has a superior effect of reducing the induction of passive systemic anaphylaxis compared to the polypeptide dimer having a low sialic acid content. Further embodiments are as follows. [Embodiment 1] A polypeptide dimer having a high content of sialic acid, comprising two monomers, each of which contains the extracellular domain of the alpha subunit of the IgE Fc receptor (FcεRIα-ECD); the monomer comprises an Fc region; the Fc region and the FcεRIα-ECD are linked via a hinge; A polypeptide dimer having a high content of sialic acid, wherein the molar ratio of sialic acid / polypeptide dimer in said polypeptide dimer having a high content of sialic acid is at least 8. [Embodiment 2] 2. A polypeptide dimer having a high content of sialic acid according to embodiment 1, wherein the extracellular domain of the alpha subunit of the IgE Fc receptor has the amino acid sequence of SEQ ID NO:1. [Embodiment 3] 2. The polypeptide dimer having a high sialic acid content according to embodiment 1, wherein the Fc region has the amino acid sequence of SEQ ID NO:2. [Embodiment 4] 2. The polypeptide dimer having a high content of sialic acid according to embodiment 1, wherein the hinge is a hinge region derived from immunoglobulin IgD or a variant thereof. [Embodiment 5] 2. The polypeptide dimer having a high content of sialic acid according to embodiment 1, wherein the sialic acid is N-acetylneuraminic acid. [Embodiment 6] 2. The polypeptide-dimer having a high content of sialic acid according to embodiment 1, wherein the molar ratio of sialic acid in said polypeptide-dimer / polypeptide-dimer is at least 10. [Embodiment 7] 7. The polypeptide dimer having a high content of sialic acid according to embodiment 6, wherein the molar ratio of sialic acid in the polypeptide dimer / polypeptide dimer is 12-25. [Embodiment 8] 5. The polypeptide dimer with a high content of sialic acid according to embodiment 4, wherein the hinge region derived from immunoglobulin IgD or a variant thereof contains at least one cysteine. [Embodiment 9] The hinge region derived from immunoglobulin IgD or a variant thereof, Arg Asn Thr Gly Arg Gly Gly Glu Glu Lys Lys Xaa1 Xaa2 Lys Glu Lys Glu Glu Gln Glu Glu Arg Glu Thr Lys Thr Pro Glu Cys Pro (SEQ ID NO: 17); Xaa1 is Lys or Gly; Xaa2 is Glu, Gly, or Ser; or Ala Gln Pro Gln Ala Glu Gly Ser Leu Ala Lys Ala Thr Thr Ala Pro Ala Thr Thr Arg Asn Thr Gly Arg Gly Gly Glu Glu Lys Lys Xaa3 Xaa4 Lys Glu Lys Glu Glu Gln Glu Glu Arg Glu Thr Lys Thr Pro Glu Cys Pro (SEQ ID NO: 18); Xaa3 is Lys or Gly; A polypeptide dimer having a high content of sialic acid according to embodiment 4, wherein Xaa4 is Glu, Gly, or Ser. [Embodiment 10] A polypeptide dimer having a high content of sialic acid as described in embodiment 4, wherein the hinge region derived from immunoglobulin IgD or a variant thereof has any one of the amino acid sequences selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 19. [Embodiment 11] A pharmaceutical composition for treating or preventing an allergic disease, comprising the polypeptide dimer having a high sialic acid content according to any one of embodiments 1 to 10. [Embodiment 12] A pharmaceutical composition for treating or preventing an allergic disease according to embodiment 11, for subcutaneous injection. [Embodiment 13] The pharmaceutical composition for treating or preventing an allergic disease according to embodiment 11, wherein the allergic disease is any one selected from the group consisting of food allergy, atopic dermatitis, asthma, allergic rhinitis, allergic conjunctivitis, allergic dermatitis, chronic idiopathic urticaria, and allergic contact dermatitis. [Embodiment 14] A transdermal patch comprising the pharmaceutical composition of embodiment 11. [Embodiment 15] A topical patch comprising the pharmaceutical composition of embodiment 11. [Embodiment 16] A food composition for improving or alleviating allergic symptoms, comprising a polypeptide dimer having a high sialic acid content according to any one of embodiments 1 to 10. [Embodiment 17] Use of a polypeptide dimer having a high content of sialic acid according to any one of embodiments 1 to 10 for preventing or treating an allergic disease. < / kd>

Claims

1. A polypeptide dimer having a high content of sialic acid, comprising two monomers, each of which contains the extracellular domain of the alpha subunit of the IgE Fc receptor (FcεRIα-ECD); the extracellular domain of the alpha subunit of the IgE Fc receptor has the amino acid sequence of SEQ ID NO:1; the monomer comprises an Fc region; the Fc region and the FcεRIα-ECD are linked via a hinge; the hinge is a hinge region derived from immunoglobulin IgD or a variant thereof; The hinge region derived from immunoglobulin IgD or a variant thereof, Arg Asn Thr GIy Arg GIy GIy Glu Glu Lys Lys Xaa1 Xaa2 Lys Glu Lys Glu Glu Gln Glu Glu Arg Glu Thr Lys Thr Pro Glu Cys Pro (SEQ ID NO: 17); Xaa1 is Gly; Xaa2 is Gly or Ser; or Ala Gln Pro Gln Ala Glu Gly Ser Leu Ala Lys Ala Thr Thr Ala Pro Ala Thr Thr Arg Asn Thr Gly Arg Gly Gly Glu Glu Lys Lys Xaa3 Xaa4 Lys Glu Lys Glu Glu Gln Glu Glu Arg Glu Thr Lys Thr Pro Glu Cys Pro (SEQ ID NO: 18), Xaa3 is Gly; Xaa4 is Gly or Ser; A polypeptide dimer having a high content of sialic acid, wherein the molar ratio of sialic acid / polypeptide dimer in said polypeptide dimer having a high content of sialic acid is 12 to 25.

2. The polypeptide dimer having a high sialic acid content described in claim 1, wherein the Fc region has the amino acid sequence of SEQ ID NO:

2.

3. The polypeptide dimer having a high sialic acid content according to claim 1, wherein the sialic acid is N-acetylneuraminic acid.

4. A polypeptide dimer having a high content of sialic acid as described in claim 1, wherein the hinge region derived from immunoglobulin IgD or a variant thereof has any one of the amino acid sequences selected from the group consisting of SEQ ID NO: 3 and SEQ ID NO:

4.

5. A pharmaceutical composition for treating or preventing an allergic disease, comprising the polypeptide dimer having a high sialic acid content according to any one of claims 1 to 4.

6. The pharmaceutical composition for treating or preventing an allergic disease according to claim 5, which is for subcutaneous injection.

7. 6. The pharmaceutical composition for treating or preventing an allergic disease according to claim 5, wherein the allergic disease is any one selected from the group consisting of food allergy, atopic dermatitis, asthma, allergic rhinitis, allergic conjunctivitis, allergic dermatitis, chronic idiopathic urticaria, and allergic contact dermatitis.

8. A transdermal patch comprising the pharmaceutical composition of claim 5.

9. A topical patch comprising the pharmaceutical composition of claim 5.

10. A food composition for improving or alleviating allergic symptoms, comprising the polypeptide dimer having a high sialic acid content according to any one of claims 1 to 4.

Citation Information

Patent Citations

  • A fusion polypeptide comprising an ige-binding domain and an hsa component and its use as a diagnostic and therapeutic agent

    JP2000516089A

  • immunoglobulin fusion protein

    JP2010531134A

  • High affinity IgE receptor alpha chain (FceRIa)

    JP2019510737A

  • Extracellular domain of the alpha subunit of the IgE Fc receptor, pharmaceutical compositions containing the same, and methods for producing the same

    JP2022176971A

  • JPP7041272B